Middle East & Africa Cancer Immunotherapy Market Size & Outlook
The cancer immunotherapy market in Middle East & Africa is expected to reach a projected revenue of US$ 12,573.9 million by 2033. A compound annual growth rate of 7.5% is expected of Middle East & Africa cancer immunotherapy market from 2026 to 2033.
The MEA cancer immunotherapy market generated a revenue of USD 7,047.7 million in 2025.
The market is expected to grow at a CAGR of 7.5% from 2026 to 2033.
In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Country-wise, Kuwait is expected to register the highest CAGR from 2026 to 2033.
MEA data book summary
Market revenue in 2025
USD 7,047.7 million
Market revenue in 2033
USD 12,573.9 million
Growth rate
7.5% (CAGR from 2026 to 2033)
Largest segment
Monoclonal antibodies
Fastest growing segment
Oncolytic Viral Therapies and Cancer Vaccines
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines
Key market players worldwide
Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR
Other key industry trends
In terms of revenue, MEA region accounted for 4.6% of the global cancer immunotherapy market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 71,890.9 million by 2033.
Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the cancer immunotherapy drugs market in MEA. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for improved treatment strategies.
MEA is increasingly focusing on genetic counselling and risk assessment for different cancer types, thereby driving personalized healthcare. Rising consumer awareness about cancer is likely to have a positive influence on market growth. Premium pricing of drugs indicates the growing need for favorable reimbursement policies, especially in low- and middle-income countries.
Middle East & Africa Cancer Immunotherapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Immunotherapy Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 65.95% in 2025.
Horizon Databook has segmented the Middle East & Africa cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.
Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the cancer immunotherapy drugs market in MEA. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for improved treatment strategies.
MEA is increasingly focusing on genetic counselling and risk assessment for different cancer types, thereby driving personalized healthcare. Rising consumer awareness about cancer is likely to have a positive influence on market growth. Premium pricing of drugs indicates the growing need for favorable reimbursement policies, especially in low- and middle-income countries.
Middle East & Africa Cancer Immunotherapy Market Product Outlook (Revenue, USD Million , 2021-2033)
Monoclonal Antibodies
Check Point Inhibitors
Oncolytic Viral Therapies and Cancer Vaccines
Middle East & Africa Cancer Immunotherapy Market Application Outlook (Revenue, USD Million , 2021-2033)
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Other Applications
Middle East & Africa Cancer Immunotherapy Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East & Africa Cancer Immunotherapy Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals and Clinics
Cancer Research Centers
Other End users
Reasons to subscribe to Cancer Immunotherapy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cancer Immunotherapy Market Outlook databook
Our clientele includes a mix of Cancer Immunotherapy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cancer Immunotherapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cancer Immunotherapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Cancer Immunotherapy Market, 2021-2033 (US$M)